Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other solid neoplasm 1

Conditions

Small Cell Lung Carcinoma 7Lung Neoplasms 3Neoplasm Metastasis 2Carcinoma, Non-Small-Cell Lung 2Solid Tumors 1Sarcoma 1Platinum-Resistant Lung Small Cell Carcinoma 1Neutropenia 1Neuroendocrine Tumors 1Mesothelioma, Malignant 1Mesothelioma 1Gastrointestinal Malignancies 1Desmoplastic Small Round Cell Tumor 1Carcinoma, Transitional Cell 1Breast Neoplasms 1Advanced Solid Tumors 1Adenoma, Islet Cell 1

Interventions

atezolizumab 3Docetaxel 3pembrolizumab 2olaparib 2lenvatinib 2Leucovorin 2Irinotecan 2Immune Checkpoint Inhibitors 2Fluorouracil 2Filgrastim 2Capecitabine 2zolbetuximab 1tomivosertib 1spartalizumab 1somatostatin receptor 2 1pralsetinib 1pegylated granulocyte colony-stimulating factor 1necitumumab 1motesanib diphosphate 1ipatasertib 1inavolisib 1entrectinib 1ensartinib 1dapagliflozin 1cobimetinib 1cemiplimab 1cat's claw extract 1balugrastim 1anlotinib 1alectinib 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 2 × Solid Tumors × PM 01183 × Clear all
NCT02451007 2019-11-19

Evaluation of the Effect of Lurbinectedin (PM01183) on Cardiac Repolarization in Patients With Selected Solid Tumors

PharmaMar

Phase 2 Completed
39 enrolled 11 charts
Other solid neoplasm

Solid Tumors

Data powered by HemOnc (CC BY 4.0) Colophon âš¡